SlideShare a Scribd company logo
Tumor Lysis Syndrome-
Management
Dr.Sreeraj Vasudevan
AIIMS 2014-2016
Outline
• Pathophysiology
• Diagnostic Criteria
• Risk Factors/Risk Group
• Prophylaxis
• Established TLS Management
Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis
with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic
circulation.
Definition of Tumour Lysis Syndrome
Cairo and Bishop definition for TLS
Laboratory TLS Clinical TLS
>2 of the following metabolic abnormalities occurring from 3
days prior to 7 days after initiation of treatment.
1. Uric acid -8 mg/dL or 25% increase from baseline
2. Potassium-6mEq/L or 25% increase from baseline
3. Phosphorus - >6.5mg/dL (children) or >4.5mg/dL (adults)
or 25% increase from baseline
4. Calcium - <7mg/dL) or 25% decrease from baseline
Laboratory TLS with any of the
following.
1. S. creatinine > 1.5x ULN
(age adjusted)
2. Seizures
3. Cardiac arrhythmia
4. Death
Howard et al criteria :
•Any symptomatic hypocalcaemia also to be considered as a lab criteria.
•Increase in the serum creatinine level of 0.3 mg/dl or the presence of oliguria, defined as an
average urine output of <0.5 ml/kg/hr. for 6 hr
Clinical features and Risk Factors
• Non-specific symptoms
• 12-72 hours after chemo or prior to chemo [Spontaneous]
• Lethargy, Nausea,Seizures
• Extreme hypoclcemia: Cramps, Tetany, Seizures, Arrhythmia, Death
• Hyperkalemia: Neuromuscular, Arrhythmia
Risk factors for the development of TLS
Characteristics Risk factors
Tumour type Acute Lymphoblastic leukemia
Burkitt’s lymphoma
High grade Non Hodgkin Lymphomas
Lymphoblastic lymphomas
Solid tumours with high proliferation -
Neuroblastoma
Tumour load Bulky disease (>10cm)
High WBC count
Elevated LDH.
Renal function Preexisting kidney injury
Urinary outflow obstruction
Nephrotoxic medications
Baseline uric acid levels Baseline hyperuricemia (>7.5 mg/d)
Chemosensitivity Effective and targeted chemo
immunotherapy.
LOW RISK  Most solid tumors
 MM
 CML
 Indolent NHL
 HL
 CLL and WBC <50 x 109/L treated only with alkylating agents
 AML and WBC <25 x 109/L and LDH <2 x ULN
 Adult intermediate grade NHL and LDH within normal limits
 Adult ALCL
INTERMEDIATE RISK  Rare, highly chemotherapy-sensitive solid tumors
 Plasma cell leukemia
 CLL treated with fludarabine, rituximab, or lenalidomide,
or venetoclax and lymph node ≥5 cm or absolute
lymphocyte count ≥25 x 109/L, and/or those with high
WBC ≥50 x 109/L
 AML with WBC 25 to 100 x 109/L OR LDH ≥2 x ULN
 Adult T cell leukemia/lymphoma, diffuse large B-cell,
transformed, and mantle cell lymphomas with LDH >
ULN, non-bulky
 Childhood ALCL stage III/IV
 ALL and WBC <100 x 109/L and LDH <2 x ULN
 Burkitt lymphoma and LDH <2 x ULN
 Childhood intermediate grade NHL stage III/IV with LDH
<2 x ULN
HIGH RISK CLL treated with venetoclax and lymph node ≥10 cm, or lymph node ≥5
cm and absolute lymphocyte count ≥25 x 109/L and elevated baseline uric acid.
AML and WBC ≥100 x 109/L
Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell
lymphomas with bulky disease and LDH ≥2 x ULN
Stage III/IV childhood diffuse large B-cell lymphoma with LDH ≥2 x ULN
Burkitt's leukemia
Other ALL and WBC ≥100 x 109/L and/or LDH ≥2 x ULN
Burkitt lymphoma stage III/IV and/or LDH ≥2 x ULN
Lymphoblastic lymphoma stage III/IV and/or LDH ≥2 x ULN
Intermediate risk disease with renal dysfunction and/or renal involvement
Intermediate risk disease with uric acid, potassium, and/or phosphate > ULN
Cairo MS, Coiffier B, Reiter A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases:
an expert TLS panel consensus. Br J Haematol 2010; 149:578
Cairo-Bishop grading system for tumour lysis syndrome.
Grade 0 Grade I Grade II Grade III Grade IV Grade V
Lab TLS - + + + + +
Creatinine 1.5xULN 1.5xULN >1.5-3xULN >3-6 x ULN >6xULN Death
Cardiac
arrhythmia
None Intervention not
required
No urgent
medical
intervention
indicated
Symptomatic and
incompletely
controlled by
medically or by
device
(defibrillator)
Life threatening
(Arrhythmia
associated with
CHF,
hypotension,
shock)
Death
Seizure None None Single
episode/episodes
of GTCS well
controlled with
AEDs, or multiple
focal motor
seizures not
interfering with
ADL
Seizures with
altered
consciousness,
poorly controlled
seizures or
breakthrough
seizures despite
medical
interventions.
Prolonged and
repetitive
seizures that are
difficult to
control.
(Status
epilepticus or
refractory
seizures)
Death
ULN – Upper limit of normal, CHF- Congestive heart failure, AEDs – Anti-epileptic drugs, ADL – activities of daily living.
Management of TLS
Delay in identifying TLS can be potentially dangerous and life
threatening
• Identification of at risk patients
• Management of risk factors
• Close monitoring
• Timely intervention
TLS Prevention
• Hydration
• Hypourecemic drugs
• Urine Alkalinisation
• Lab monitoring
TLS Prevention: Hydration
• Wide bore IV access
• IV hydration — Aggressive IV hydration is the cornerstone of preventing TLS
• Recommended prior to therapy in patients at intermediate or high risk for TLS
• The goal of IV hydration :
• A 2008 International Expert Panel on TLS recommended that both children
and adults at risk for TLS initially receive 2 to 3 L/m2 per day of IV fluid
• or 200 mL/kg per day in children weighing ≤10 kg
• Urine output : to maintain within a range of 80 to 100 mL/m2 per hour
• Diuretics can be used to maintain the urine output, if necessary
• Choice of Diuretic: Frusemide
• Choice of Fluid: ?
• Optimal Duration: ?
Coiffier, B., et al., Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin
Oncol, 2008. 26(16): p. 2767-78.
TLS Prevention:Urinary alkalinization
• Benefit unclear / controversial
• Sodium Bicarbonate only if metabolic acidosis
• If alkalinization is used, it should be initiated when the serum uric acid
level is high and discontinued when hyperphosphatemia develops
• Not required in patients receiving rasburicase
For Against
No proven efficacy documented
Urine pH > 6.5 improve Uric acid
solubility
0.9% NS hydration itself is as effective in
preventing uric acid precipitation
Alkalinization promote deposition of
calcium phosphate crystals in tissues
including heart
TLS Prevention : Hypouricemic agents
TLS Prevention : Hypouricemic agents
Allopurinol
• Recommendation: For the initial management of adult and pediatric
patients at intermediate risk for TLS [Pre treatment Uric Acid
<8mg/dL]
• Allopurinol effectively decreases the formation of new uric acid
TLS Prevention : Hypouricemic agents
Allopurinol
• Limitations :
• Preexisting serum uric acid is NOT reduced
• XANTHINURIA, deposition of xanthine crystals in the renal tubules, and acute
kidney injury
• Drug interaction
• Hypersensitivity reactions
• Dose and administration :
• Adults -100 mg/m2 every eight hours (maximum 800 mg per day)
• Children-50 to 100 mg/m2 every eight hours (maximum 300 mg/m2 per day)
or 10 mg/kg per day in divided doses every eight hours
• The dose must be reduced by 50 percent in the setting of acute kidney injury
TLS Prevention : Hypouricemic agents
Rasburicase
• Recommendations: For the initial management of most pediatric and
adult patients at high risk for TLS ,especially with impaired renal or
cardiac function
TLS Prevention : Hypouricemic agents
Rasburicase
• Rapid breakdown & Sustained Response
Stanton C. Goldman et al. Blood 2001;97:2998-3003
TLS Prevention : Hypouricemic agents
Rasburicase
• Dosing and administration — The EMA and FDA dosing guidelines both
recommend a rasburicase dose of 0.2 mg/kg once daily for up to five (FDA)
or seven (EMA) days
• Expert Consensus Panel
• High-risk patients or a baseline uric acid level >7.5 mg/dL (446 micromol/L) –
rasburicase 0.2 mg/kg
• Intermediate-risk patients with baseline uric acid ≤7.5 mg/dL – rasburicase 0.15 mg/kg
• Length of treatment has generally been based on clinical judgement
• Allopurinol can a be started once the serum uric acid is brought down to
adequately low levels
• Responses to rasburicase are dose-related
TLS Prevention : Hypouricemic agents
Rasburicase
Lower Dose / Shorter duration Rasburicase:
• Based upon these data, single-dose rasburicase may be used in patients at intermediate risk
(0.15 mg/kg [ rounded up to 3 mg or 6 mg depending on body weight]) or high risk (0.2 mg/kg) of TLS
• These patients receive allopurinol after rasburicase treatment
• Uric acid levels should be monitored closely and additional doses of rasburicase given if and when
hyperuricemia recurs
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.,Feng X etalJ Clin Pharm
Ther. 2013;38(4):301
TLS Prevention : Hypouricemic agents
Rasburicase
• Contraindications and restrictions
• Hemolysis in patients with G6PD deficiency
• Anaphylaxis
• Methemoglobinemia
• Spuriously low uric acid measurements
• Rasburicase within blood samples causes enzymatic degradation of uric acid ex vivo if
the blood samples are left at room temperature, resulting in spuriously low serum uric
acid concentrations, and hence missing the diagnosis of ongoing TLS.
• Blood samples for determination of uric acid concentrations should be collected in a pre-
chilled tube, immediately placed on ice, and the assay completed within four hours, if
possible
• Febuxostat
• Available data on efficacy and safety are insufficient to suggest the use
of febuxostat as an alternative to allopurinol to prevent TLS in patients at
intermediate to high risk for TLS.
• Febuxostat may be used judiciously in patients with hyperuricemia who
cannot tolerate allopurinol in a setting in which rasburicase is either not
available or contraindicated
TLS Prevention:Monitoring Guidelines
• Urine output and serial assays of electrolytes and serum uric acid
• 2008 International Expert Panel guidelines recommendations for
monitoring in high risk of TLS
• laboratory and clinical TLS parameters four to six hours after the initiation of
chemotherapy and every four to eight hours thereafter
• For all patients receiving rasburicase (hence deemed at high risk for TLS),
serum uric acid should be reevaluated four hours after administration of the
first dose, and every 6 to 12 hours
• Adults at intermediate risk for TLS should be monitored for at least 24 hours
after completion of chemotherapy
• If TLS has not occurred within 72 hours of multiagent chemotherapy, the
likelihood of TLS is very low
TREATMENT OF ESTABLISHED TLS
• Despite appropriate preventive measures, approximately 3 to 5 percent of
patients develop laboratory and/or clinical evidence of TLS, despite the
prophylactic use of rasburicase
• Intensive supportive care with continuous cardiac monitoring and
measurement of electrolytes, creatinine, and uric acid every four to six
hours
• Combination of
• Treating specific electrolyte abnormalities
• Use of rasburicase at 0.2 mg/kg (if it was not given initially) with repeated doses as
necessary
• Attempting to wash out the obstructing uric acid crystals with fluids with or without
a loop diuretic
• Appropriate use of renal replacement therapy
Hyperphoshatemia Recommendations:
Moderate, ≥6.5 mg/dL Restrict phosphate intake (avoid IV and oral phosphate;
limit dietary sources)
Phosphate binders:
• Calcium acetate
:
Adult: 2 to 3 tabs (1334 to 2668
mg) with each meal; or
• Calcium carbonate:Adult: 1 to 2 grams with each
meal; Pediatric: 30 to 40 mg/kg with each meal;
or
• Sevelamer:Adult: 800 to 1600 mg with each
meal; Pediatric: 40 to 54 mg/kg with each meal;
or
• Lanthanum carbonate :Adult: 500 to 1000 mg
with each meal or
• Aluminum hydroxide :Adult: 300 to 600 mg with
each meal; Pediatric: 12.5 to 37.5 mg/kg four
times daily with meals; (avoid use in patients with
renal insufficiency)
Severe
Dialysis, CAVH, CVVH, CAVHD, or CVVHD
Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol
2008; 26:2767.
Hypocalcemia, total serum calcium ≤7 mg/dLor ionized calcium ≤3.2 mg/dL
Asymptomatic No Therapy
Symptomatic Calcium gluconate administered slowly with ECG
monitoring
Patients with acute hypocalcemia and
hyperphosphatemia should not be treated with
calcium until the hyperphosphatemia is corrected
(unless they have tetany or a cardiac arrhythmia from
hypocalcemia)
Calcium gluconate:
Adult: 1 gram (10 mL of 10 percent solution)
Pediatric: 50 to 100 mg/kg
Slow IV infusion (maximum 50 to 100 mg per
minute) in large vein
May be repeated after 5 to 10 minutes if
symptoms or ECG changes persist.
Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol
2008; 26:2767.
Hyperkalemia
Moderate and asymptomatic, ≥6.0 mEq/L Avoid IV and oral potassium
ECG and cardiac rhythm monitoring
Sodium polystyrene sulfonate
Adult: 15 to 30 grams orally
Pediatric: 1 gram/kg orally.
Onset 1 to 2 hours.
Repeat every 4 to 6 hours up to four times daily
as needed based on repeat serum K+ level
Severe (>7.0 mEq/L) and/or symptomatic For patients with ECG changes (widening of the QRS
complex or loss of p-waves but not peaked t-waves
alone), give calcium gluconate by slow IV infusion to
prevent life-threatening arrhythmias
To temporarily shift potassium into cells:
IV Glucose with Insulin
If acidosis: Soda Bicarbonate
Salbutamol Nebulisation
Dialysis
Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;
26:2767.
Indications for renal replacement therapy
• Reduced need with Rasburicase
• Indication for RRT
• Severe oliguria or anuria
• Intractable fluid overload
• Persistent hyperkalemia
• Hyperphosphatemia-induced symptomatic hypocalcemia
• A calcium-phosphate product ≥70 mg2/dL2
• The prognosis for complete recovery of renal function is excellent if dialysis
is initiated early to rapidly reduce serum uric acid and phosphate
concentrations
• Continuous renal replacement therapies may be better tolerated for
Hyperphosphatemia
Summary
• TLS is an oncological emergency with High treatment cost, morbidity
and mortality if not prevented.
• Hydration is corner stone in management
• Intermediate risk patient with Uric Acid < 8 should receive Allopurinol
• High risk patient or Established TLS should receive Rasburicase ,Single
dose may be effective.
• Continuous cardiac monitoring with frequent Electrolyte
measurement is needed
• Management of dyselectrolytemia with judicious renal replacement
therapy is needed in established TLS
Bibliography
1. Hande, K.R. and G.C. Garrow, Acute tumor lysis syndrome in patients with high-
grade non-Hodgkin's lymphoma. Am J Med, 1993. 94(2): p. 133-9.
2. Cairo, M.S. and M. Bishop, Tumour lysis syndrome: new therapeutic strategies and
classification. Br J Haematol, 2004. 127(1): p. 3-11.
3. Howard, S.C., D.P. Jones, and C.H. Pui, The tumor lysis syndrome. N Engl J Med,
2011. 364(19): p. 1844-54.
4. Coiffier, B., et al., Guidelines for the management of pediatric and adult tumor lysis
syndrome: an evidence-based review. J Clin Oncol, 2008. 26(16): p. 2767-78.
5. Tosi, P., et al., Consensus conference on the management of tumor lysis syndrome.
Haematologica, 2008. 93(12): p. 1877-85.
6. Will, A. and E. Tholouli, The clinical management of tumour lysis syndrome in
haematological malignancies. Br J Haematol, 2011. 154(1): p. 3-13.
• Thank You

More Related Content

Similar to TLS Final.ppt

Oncological Emergencies
Oncological EmergenciesOncological Emergencies
Oncological Emergencies
Amna Ahmed
 
Tumor Lysis Syndrome
Tumor Lysis SyndromeTumor Lysis Syndrome
Tumor Lysis Syndrome
CSN Vittal
 
TUMOR LYSIS SYNDROME
TUMOR LYSIS SYNDROMETUMOR LYSIS SYNDROME
TUMOR LYSIS SYNDROMEderosaMSKCC
 
Blood Basics TLS.pptx
Blood Basics TLS.pptxBlood Basics TLS.pptx
Blood Basics TLS.pptx
Dibyajyoti Prusty
 
SLE: present guidelines and consensus
SLE: present guidelines and consensusSLE: present guidelines and consensus
SLE: present guidelines and consensusVishal Golay
 
Hl &amp; Tls Presentation
Hl &amp; Tls PresentationHl &amp; Tls Presentation
Hl &amp; Tls Presentationflutterbye_xo
 
Tumour lysis sydrome
Tumour lysis sydromeTumour lysis sydrome
Tumour lysis sydrome
Deepika Malik
 
Tumor-Lysis-Syndrome (TLS) - Oncology Emergency
Tumor-Lysis-Syndrome (TLS) - Oncology EmergencyTumor-Lysis-Syndrome (TLS) - Oncology Emergency
Tumor-Lysis-Syndrome (TLS) - Oncology Emergency
doctor350343
 
Oncologies_Emergency.pptx
Oncologies_Emergency.pptxOncologies_Emergency.pptx
Oncologies_Emergency.pptx
MuhammadBinAbdullah8
 
Dyslipidaemia presentation
Dyslipidaemia presentationDyslipidaemia presentation
Dyslipidaemia presentation
rajeetam123
 
TLS (National Cancer Institute)
TLS (National Cancer Institute)TLS (National Cancer Institute)
TLS (National Cancer Institute)Mohamed Moustafa
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
Lord Ceasar
 
Tumor Lysis Syndrome2
Tumor Lysis Syndrome2Tumor Lysis Syndrome2
Tumor Lysis Syndrome2calaf0618
 
Thalassemia and Pregnancy
Thalassemia and PregnancyThalassemia and Pregnancy
Thalassemia and Pregnancy
Nishkarsh Bansal
 
hypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdfhypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdf
ssuser1944d2
 
hypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdfhypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdf
VishnuR4970
 
Hypercalcemia
HypercalcemiaHypercalcemia
Hypercalcemia
Dr. Lala Shourav Das
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndromeds Reddy
 
Tumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptxTumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptx
AzazhuAbate
 
Tumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptxTumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptx
AzazhuAbate
 

Similar to TLS Final.ppt (20)

Oncological Emergencies
Oncological EmergenciesOncological Emergencies
Oncological Emergencies
 
Tumor Lysis Syndrome
Tumor Lysis SyndromeTumor Lysis Syndrome
Tumor Lysis Syndrome
 
TUMOR LYSIS SYNDROME
TUMOR LYSIS SYNDROMETUMOR LYSIS SYNDROME
TUMOR LYSIS SYNDROME
 
Blood Basics TLS.pptx
Blood Basics TLS.pptxBlood Basics TLS.pptx
Blood Basics TLS.pptx
 
SLE: present guidelines and consensus
SLE: present guidelines and consensusSLE: present guidelines and consensus
SLE: present guidelines and consensus
 
Hl &amp; Tls Presentation
Hl &amp; Tls PresentationHl &amp; Tls Presentation
Hl &amp; Tls Presentation
 
Tumour lysis sydrome
Tumour lysis sydromeTumour lysis sydrome
Tumour lysis sydrome
 
Tumor-Lysis-Syndrome (TLS) - Oncology Emergency
Tumor-Lysis-Syndrome (TLS) - Oncology EmergencyTumor-Lysis-Syndrome (TLS) - Oncology Emergency
Tumor-Lysis-Syndrome (TLS) - Oncology Emergency
 
Oncologies_Emergency.pptx
Oncologies_Emergency.pptxOncologies_Emergency.pptx
Oncologies_Emergency.pptx
 
Dyslipidaemia presentation
Dyslipidaemia presentationDyslipidaemia presentation
Dyslipidaemia presentation
 
TLS (National Cancer Institute)
TLS (National Cancer Institute)TLS (National Cancer Institute)
TLS (National Cancer Institute)
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
 
Tumor Lysis Syndrome2
Tumor Lysis Syndrome2Tumor Lysis Syndrome2
Tumor Lysis Syndrome2
 
Thalassemia and Pregnancy
Thalassemia and PregnancyThalassemia and Pregnancy
Thalassemia and Pregnancy
 
hypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdfhypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdf
 
hypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdfhypercalcemia-171125132212.pdf
hypercalcemia-171125132212.pdf
 
Hypercalcemia
HypercalcemiaHypercalcemia
Hypercalcemia
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
 
Tumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptxTumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptx
 
Tumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptxTumer lysis syndrom by Azazhu.pptx
Tumer lysis syndrom by Azazhu.pptx
 

Recently uploaded

Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Temporomandibular Joint By RABIA INAM GANDAPORE.pptx
Temporomandibular Joint By RABIA INAM GANDAPORE.pptxTemporomandibular Joint By RABIA INAM GANDAPORE.pptx
Temporomandibular Joint By RABIA INAM GANDAPORE.pptx
Dr. Rabia Inam Gandapore
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
Dr. Rabia Inam Gandapore
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
Sai Sailesh Kumar Goothy
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
Dr Maria Tamanna
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 

Recently uploaded (20)

Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Temporomandibular Joint By RABIA INAM GANDAPORE.pptx
Temporomandibular Joint By RABIA INAM GANDAPORE.pptxTemporomandibular Joint By RABIA INAM GANDAPORE.pptx
Temporomandibular Joint By RABIA INAM GANDAPORE.pptx
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Vision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of opticsVision-1.pptx, Eye structure, basics of optics
Vision-1.pptx, Eye structure, basics of optics
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Colonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implicationsColonic and anorectal physiology with surgical implications
Colonic and anorectal physiology with surgical implications
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 

TLS Final.ppt

  • 2. Outline • Pathophysiology • Diagnostic Criteria • Risk Factors/Risk Group • Prophylaxis • Established TLS Management
  • 3. Tumor lysis syndrome (TLS) is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation.
  • 4. Definition of Tumour Lysis Syndrome Cairo and Bishop definition for TLS Laboratory TLS Clinical TLS >2 of the following metabolic abnormalities occurring from 3 days prior to 7 days after initiation of treatment. 1. Uric acid -8 mg/dL or 25% increase from baseline 2. Potassium-6mEq/L or 25% increase from baseline 3. Phosphorus - >6.5mg/dL (children) or >4.5mg/dL (adults) or 25% increase from baseline 4. Calcium - <7mg/dL) or 25% decrease from baseline Laboratory TLS with any of the following. 1. S. creatinine > 1.5x ULN (age adjusted) 2. Seizures 3. Cardiac arrhythmia 4. Death Howard et al criteria : •Any symptomatic hypocalcaemia also to be considered as a lab criteria. •Increase in the serum creatinine level of 0.3 mg/dl or the presence of oliguria, defined as an average urine output of <0.5 ml/kg/hr. for 6 hr
  • 5. Clinical features and Risk Factors • Non-specific symptoms • 12-72 hours after chemo or prior to chemo [Spontaneous] • Lethargy, Nausea,Seizures • Extreme hypoclcemia: Cramps, Tetany, Seizures, Arrhythmia, Death • Hyperkalemia: Neuromuscular, Arrhythmia
  • 6. Risk factors for the development of TLS Characteristics Risk factors Tumour type Acute Lymphoblastic leukemia Burkitt’s lymphoma High grade Non Hodgkin Lymphomas Lymphoblastic lymphomas Solid tumours with high proliferation - Neuroblastoma Tumour load Bulky disease (>10cm) High WBC count Elevated LDH. Renal function Preexisting kidney injury Urinary outflow obstruction Nephrotoxic medications Baseline uric acid levels Baseline hyperuricemia (>7.5 mg/d) Chemosensitivity Effective and targeted chemo immunotherapy.
  • 7. LOW RISK  Most solid tumors  MM  CML  Indolent NHL  HL  CLL and WBC <50 x 109/L treated only with alkylating agents  AML and WBC <25 x 109/L and LDH <2 x ULN  Adult intermediate grade NHL and LDH within normal limits  Adult ALCL INTERMEDIATE RISK  Rare, highly chemotherapy-sensitive solid tumors  Plasma cell leukemia  CLL treated with fludarabine, rituximab, or lenalidomide, or venetoclax and lymph node ≥5 cm or absolute lymphocyte count ≥25 x 109/L, and/or those with high WBC ≥50 x 109/L  AML with WBC 25 to 100 x 109/L OR LDH ≥2 x ULN  Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell lymphomas with LDH > ULN, non-bulky  Childhood ALCL stage III/IV  ALL and WBC <100 x 109/L and LDH <2 x ULN  Burkitt lymphoma and LDH <2 x ULN  Childhood intermediate grade NHL stage III/IV with LDH <2 x ULN HIGH RISK CLL treated with venetoclax and lymph node ≥10 cm, or lymph node ≥5 cm and absolute lymphocyte count ≥25 x 109/L and elevated baseline uric acid. AML and WBC ≥100 x 109/L Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell lymphomas with bulky disease and LDH ≥2 x ULN Stage III/IV childhood diffuse large B-cell lymphoma with LDH ≥2 x ULN Burkitt's leukemia Other ALL and WBC ≥100 x 109/L and/or LDH ≥2 x ULN Burkitt lymphoma stage III/IV and/or LDH ≥2 x ULN Lymphoblastic lymphoma stage III/IV and/or LDH ≥2 x ULN Intermediate risk disease with renal dysfunction and/or renal involvement Intermediate risk disease with uric acid, potassium, and/or phosphate > ULN Cairo MS, Coiffier B, Reiter A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578
  • 8. Cairo-Bishop grading system for tumour lysis syndrome. Grade 0 Grade I Grade II Grade III Grade IV Grade V Lab TLS - + + + + + Creatinine 1.5xULN 1.5xULN >1.5-3xULN >3-6 x ULN >6xULN Death Cardiac arrhythmia None Intervention not required No urgent medical intervention indicated Symptomatic and incompletely controlled by medically or by device (defibrillator) Life threatening (Arrhythmia associated with CHF, hypotension, shock) Death Seizure None None Single episode/episodes of GTCS well controlled with AEDs, or multiple focal motor seizures not interfering with ADL Seizures with altered consciousness, poorly controlled seizures or breakthrough seizures despite medical interventions. Prolonged and repetitive seizures that are difficult to control. (Status epilepticus or refractory seizures) Death ULN – Upper limit of normal, CHF- Congestive heart failure, AEDs – Anti-epileptic drugs, ADL – activities of daily living.
  • 9. Management of TLS Delay in identifying TLS can be potentially dangerous and life threatening • Identification of at risk patients • Management of risk factors • Close monitoring • Timely intervention
  • 10. TLS Prevention • Hydration • Hypourecemic drugs • Urine Alkalinisation • Lab monitoring
  • 11. TLS Prevention: Hydration • Wide bore IV access • IV hydration — Aggressive IV hydration is the cornerstone of preventing TLS • Recommended prior to therapy in patients at intermediate or high risk for TLS • The goal of IV hydration : • A 2008 International Expert Panel on TLS recommended that both children and adults at risk for TLS initially receive 2 to 3 L/m2 per day of IV fluid • or 200 mL/kg per day in children weighing ≤10 kg • Urine output : to maintain within a range of 80 to 100 mL/m2 per hour • Diuretics can be used to maintain the urine output, if necessary • Choice of Diuretic: Frusemide • Choice of Fluid: ? • Optimal Duration: ? Coiffier, B., et al., Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol, 2008. 26(16): p. 2767-78.
  • 12. TLS Prevention:Urinary alkalinization • Benefit unclear / controversial • Sodium Bicarbonate only if metabolic acidosis • If alkalinization is used, it should be initiated when the serum uric acid level is high and discontinued when hyperphosphatemia develops • Not required in patients receiving rasburicase For Against No proven efficacy documented Urine pH > 6.5 improve Uric acid solubility 0.9% NS hydration itself is as effective in preventing uric acid precipitation Alkalinization promote deposition of calcium phosphate crystals in tissues including heart
  • 13. TLS Prevention : Hypouricemic agents
  • 14. TLS Prevention : Hypouricemic agents Allopurinol • Recommendation: For the initial management of adult and pediatric patients at intermediate risk for TLS [Pre treatment Uric Acid <8mg/dL] • Allopurinol effectively decreases the formation of new uric acid
  • 15. TLS Prevention : Hypouricemic agents Allopurinol • Limitations : • Preexisting serum uric acid is NOT reduced • XANTHINURIA, deposition of xanthine crystals in the renal tubules, and acute kidney injury • Drug interaction • Hypersensitivity reactions • Dose and administration : • Adults -100 mg/m2 every eight hours (maximum 800 mg per day) • Children-50 to 100 mg/m2 every eight hours (maximum 300 mg/m2 per day) or 10 mg/kg per day in divided doses every eight hours • The dose must be reduced by 50 percent in the setting of acute kidney injury
  • 16. TLS Prevention : Hypouricemic agents Rasburicase • Recommendations: For the initial management of most pediatric and adult patients at high risk for TLS ,especially with impaired renal or cardiac function
  • 17. TLS Prevention : Hypouricemic agents Rasburicase • Rapid breakdown & Sustained Response Stanton C. Goldman et al. Blood 2001;97:2998-3003
  • 18. TLS Prevention : Hypouricemic agents Rasburicase • Dosing and administration — The EMA and FDA dosing guidelines both recommend a rasburicase dose of 0.2 mg/kg once daily for up to five (FDA) or seven (EMA) days • Expert Consensus Panel • High-risk patients or a baseline uric acid level >7.5 mg/dL (446 micromol/L) – rasburicase 0.2 mg/kg • Intermediate-risk patients with baseline uric acid ≤7.5 mg/dL – rasburicase 0.15 mg/kg • Length of treatment has generally been based on clinical judgement • Allopurinol can a be started once the serum uric acid is brought down to adequately low levels • Responses to rasburicase are dose-related
  • 19. TLS Prevention : Hypouricemic agents Rasburicase Lower Dose / Shorter duration Rasburicase: • Based upon these data, single-dose rasburicase may be used in patients at intermediate risk (0.15 mg/kg [ rounded up to 3 mg or 6 mg depending on body weight]) or high risk (0.2 mg/kg) of TLS • These patients receive allopurinol after rasburicase treatment • Uric acid levels should be monitored closely and additional doses of rasburicase given if and when hyperuricemia recurs Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.,Feng X etalJ Clin Pharm Ther. 2013;38(4):301
  • 20. TLS Prevention : Hypouricemic agents Rasburicase • Contraindications and restrictions • Hemolysis in patients with G6PD deficiency • Anaphylaxis • Methemoglobinemia • Spuriously low uric acid measurements • Rasburicase within blood samples causes enzymatic degradation of uric acid ex vivo if the blood samples are left at room temperature, resulting in spuriously low serum uric acid concentrations, and hence missing the diagnosis of ongoing TLS. • Blood samples for determination of uric acid concentrations should be collected in a pre- chilled tube, immediately placed on ice, and the assay completed within four hours, if possible
  • 21. • Febuxostat • Available data on efficacy and safety are insufficient to suggest the use of febuxostat as an alternative to allopurinol to prevent TLS in patients at intermediate to high risk for TLS. • Febuxostat may be used judiciously in patients with hyperuricemia who cannot tolerate allopurinol in a setting in which rasburicase is either not available or contraindicated
  • 22. TLS Prevention:Monitoring Guidelines • Urine output and serial assays of electrolytes and serum uric acid • 2008 International Expert Panel guidelines recommendations for monitoring in high risk of TLS • laboratory and clinical TLS parameters four to six hours after the initiation of chemotherapy and every four to eight hours thereafter • For all patients receiving rasburicase (hence deemed at high risk for TLS), serum uric acid should be reevaluated four hours after administration of the first dose, and every 6 to 12 hours • Adults at intermediate risk for TLS should be monitored for at least 24 hours after completion of chemotherapy • If TLS has not occurred within 72 hours of multiagent chemotherapy, the likelihood of TLS is very low
  • 23. TREATMENT OF ESTABLISHED TLS • Despite appropriate preventive measures, approximately 3 to 5 percent of patients develop laboratory and/or clinical evidence of TLS, despite the prophylactic use of rasburicase • Intensive supportive care with continuous cardiac monitoring and measurement of electrolytes, creatinine, and uric acid every four to six hours • Combination of • Treating specific electrolyte abnormalities • Use of rasburicase at 0.2 mg/kg (if it was not given initially) with repeated doses as necessary • Attempting to wash out the obstructing uric acid crystals with fluids with or without a loop diuretic • Appropriate use of renal replacement therapy
  • 24. Hyperphoshatemia Recommendations: Moderate, ≥6.5 mg/dL Restrict phosphate intake (avoid IV and oral phosphate; limit dietary sources) Phosphate binders: • Calcium acetate : Adult: 2 to 3 tabs (1334 to 2668 mg) with each meal; or • Calcium carbonate:Adult: 1 to 2 grams with each meal; Pediatric: 30 to 40 mg/kg with each meal; or • Sevelamer:Adult: 800 to 1600 mg with each meal; Pediatric: 40 to 54 mg/kg with each meal; or • Lanthanum carbonate :Adult: 500 to 1000 mg with each meal or • Aluminum hydroxide :Adult: 300 to 600 mg with each meal; Pediatric: 12.5 to 37.5 mg/kg four times daily with meals; (avoid use in patients with renal insufficiency) Severe Dialysis, CAVH, CVVH, CAVHD, or CVVHD Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.
  • 25. Hypocalcemia, total serum calcium ≤7 mg/dLor ionized calcium ≤3.2 mg/dL Asymptomatic No Therapy Symptomatic Calcium gluconate administered slowly with ECG monitoring Patients with acute hypocalcemia and hyperphosphatemia should not be treated with calcium until the hyperphosphatemia is corrected (unless they have tetany or a cardiac arrhythmia from hypocalcemia) Calcium gluconate: Adult: 1 gram (10 mL of 10 percent solution) Pediatric: 50 to 100 mg/kg Slow IV infusion (maximum 50 to 100 mg per minute) in large vein May be repeated after 5 to 10 minutes if symptoms or ECG changes persist. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.
  • 26. Hyperkalemia Moderate and asymptomatic, ≥6.0 mEq/L Avoid IV and oral potassium ECG and cardiac rhythm monitoring Sodium polystyrene sulfonate Adult: 15 to 30 grams orally Pediatric: 1 gram/kg orally. Onset 1 to 2 hours. Repeat every 4 to 6 hours up to four times daily as needed based on repeat serum K+ level Severe (>7.0 mEq/L) and/or symptomatic For patients with ECG changes (widening of the QRS complex or loss of p-waves but not peaked t-waves alone), give calcium gluconate by slow IV infusion to prevent life-threatening arrhythmias To temporarily shift potassium into cells: IV Glucose with Insulin If acidosis: Soda Bicarbonate Salbutamol Nebulisation Dialysis Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767.
  • 27. Indications for renal replacement therapy • Reduced need with Rasburicase • Indication for RRT • Severe oliguria or anuria • Intractable fluid overload • Persistent hyperkalemia • Hyperphosphatemia-induced symptomatic hypocalcemia • A calcium-phosphate product ≥70 mg2/dL2 • The prognosis for complete recovery of renal function is excellent if dialysis is initiated early to rapidly reduce serum uric acid and phosphate concentrations • Continuous renal replacement therapies may be better tolerated for Hyperphosphatemia
  • 28. Summary • TLS is an oncological emergency with High treatment cost, morbidity and mortality if not prevented. • Hydration is corner stone in management • Intermediate risk patient with Uric Acid < 8 should receive Allopurinol • High risk patient or Established TLS should receive Rasburicase ,Single dose may be effective. • Continuous cardiac monitoring with frequent Electrolyte measurement is needed • Management of dyselectrolytemia with judicious renal replacement therapy is needed in established TLS
  • 29. Bibliography 1. Hande, K.R. and G.C. Garrow, Acute tumor lysis syndrome in patients with high- grade non-Hodgkin's lymphoma. Am J Med, 1993. 94(2): p. 133-9. 2. Cairo, M.S. and M. Bishop, Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol, 2004. 127(1): p. 3-11. 3. Howard, S.C., D.P. Jones, and C.H. Pui, The tumor lysis syndrome. N Engl J Med, 2011. 364(19): p. 1844-54. 4. Coiffier, B., et al., Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol, 2008. 26(16): p. 2767-78. 5. Tosi, P., et al., Consensus conference on the management of tumor lysis syndrome. Haematologica, 2008. 93(12): p. 1877-85. 6. Will, A. and E. Tholouli, The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol, 2011. 154(1): p. 3-13.